bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
140 hedge funds and large institutions have $32.9M invested in bluebird bio in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 39 increasing their positions, 44 reducing their positions, and 26 closing their positions.
0.42% less ownership
Funds ownership: 2.04% → 1.62% (-0.42%)
7% less funds holding
Funds holding: 150 → 140 (-10)
11% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 44
38% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 26
40% less call options, than puts
Call options by funds: $295K | Put options by funds: $492K
58% less capital invested
Capital invested by funds: $78.4M → $32.9M (-$45.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$1.36M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$1.08M |
| 3 |
LPC
Lion Point Capital
New York
|
+$748K |
| 4 |
Morgan Stanley
New York
|
+$376K |
| 5 |
Goldman Sachs
New York
|
+$331K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$6.29M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$3.35M |
| 3 |
Millennium Management
New York
|
-$2.94M |
| 4 |
MIC
Maxi Investments CY
Limassol,
Cyprus
|
-$1.25M |
| 5 |
BL
Bleichroeder LP
New York
|
-$1.02M |
BLUE Hedge Fund Activity: Q3 2024 in Review
140 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q3 2024, worth a combined $32.9M — down 58% from $78.4M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of BLUE and 16 opened new positions — a net loss of 10 holders — while 44 trimmed existing stakes and 39 added.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $1.36M. The largest seller was Ameriprise, exiting entirely with an estimated $6.29M sold.
- 140 institutional investors held bluebird bio (BLUE) as of Q3 2024, down from 150 in Q2 2024.
- Funds reported $32.9M of bluebird bio stock for Q3 2024, down 58% quarter-over-quarter.
- 16 funds opened new bluebird bio positions in Q3 2024 and 26 closed out, a net change of -10 holders.
- The largest bluebird bio buyer in Q3 2024 was Avidity Partners Management, an estimated $1.36M added.
- The largest bluebird bio seller in Q3 2024 was Ameriprise, an estimated $6.29M sold.
Based on aggregated 13F filings for Q3 2024.